Evidence map›Paper›PMID 39207609›Full record

ArticleEJNMMI physics2024

Feasibility of a deep-inspiration breath-hold [

Haiqiong Zhang, Meixi Liu, Ximin Shi, Jiangyu Ma, Chao Ren, Zhenghai Huang, Ying Wang, Hongli Jing, Li Huo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haiqiong ZhangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Meixi LiuDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Ximin ShiDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Jiangyu MaDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Chao RenDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Zhenghai HuangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Ying WangCentral Research Institute, United Imaging Healthcare, Shanghai, 201815, China.
Hongli JingDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Li HuoDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. huoli@pumch.cn.ORCID http://orcid.org/0000-0003-1216-083X

Funding

CAMS innovation fund for medical science CIFMS-2021-I2M-1-002CAMS innovation fund for medical science CIFMS-2021-I2M-1-003CAMS innovation fund for medical science CIFMS-2021-I2M-1-025CAMS innovation fund for medical science CIFMS-2022-I2M-JB-001High-level Hospital Construction Project of Guangdong Provincial People's Hospital XH-QN-012KNational High Level Hospital Clinical Research Funding 2022-PUMCH-B-071National High Level Hospital Clinical Research Funding 2022-PUMCH-C-037National High Level Hospital Clinical Research Funding 2022-PUMCH-D-001National Key Research and Development Program of China No. 2016YFC0901500
6 · The paper itself

Abstract

purposesTo explore the clinical feasibility and efficacy of a deep inspiration breath-hold (BH) PET/CT using [

methodsTwenty-three patients underwent a free-breath (FB) whole-body PET/CT, including a 10 min/bed scan for the upper abdomen with a vital signal monitoring for respiratory gating (RG) followed by a 20-second BH PET/CT covering the same axial range. For the upper abdomen bed, the following PET series was reconstructed: a 2-min FB PET; RG PET (6 bins); a 20-second and 15-second BH PET (BH_15 and BH_20). Semi-quantitative analysis was performed to compare liver SUV

resultsQuantitative analysis on overall lesions (n = 78) revealed higher SUV

conclusionThe BH PET/CT using [

Indexed as

Deep-inspiration breath-holdFree-breathNeuroendocrine tumorsRespiratory gating

Identifiers

PMID39207609
PMCPMC11362407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.